Newly activated UI Cancer Center clinical trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about a study, please email [email protected] or call 312-355-5112.

C3441020: A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients With Early Triple-Negative Breast Cancer

This is a study for newly diagnosed women and men with BRCA+, triple negative breast cancer. The treatment is monotherapy oral Talazoparib for 24 weeks followed by surgery.

Sponsor: Pfizer
Principle Investigator: Oana Danciu, MD

S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

This Phase II trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Sponsor: Southwest Oncology Group
Principle Investigator: Daniel Moreira, MD

Translate »